In April 2026, medical literature highlighted an unconventional gastroenterology intervention: treating severe, treatment-resistant fecalomas in elderly patients using Coca-Cola via targeted enemas. While offering low-cost clinical utility, this protocol remains strictly experimental.
The Bottom Line
- Clinical Application: Medical case studies from 2014 to 2026 document successful fecaloma and phytobezoar dissolutions using standard and zero-sugar variants of Coca-Cola.
Decoding the Clinical Mechanism Behind Carbonated Interventions
When conservative treatments fail—as they do in about 29% of cases according to the data of the literature—hospital clinicians occasionally leverage the chemical properties of carbonated soft drinks. According to case reports published in Cureus in April 2026, medical teams in Miami managed an 82-year-old patient suffering from a 12.2 x 10.5 cm fecaloma by administering one liter of classic Coca-Cola beverage via a controlled rectal tube. The scientific rationale relies on a low pH level near 2.5, the mucolytic activity of sodium bicarbonate, and the mechanical agitation generated by carbon dioxide bubbles. These combined properties mirror techniques historically deployed against gastric phytobezoards, which achieved a global success rate of 91.3% using Coca-Cola in a review of the literature published in 2013.
Market Realities and Corporate Financial Performance
| Metric / Indicator | Corporate Baseline Context | Clinical Application Context |
|---|---|---|
| Primary Revenue Driver | Global retail beverage distribution | Zero commercial revenue generation |
| Regulatory Oversight | FDA / FTC consumer packaging standards | Hospital IRB / Institutional medical protocols |
| Volume Consumption | Billions of daily consumer servings | Fractional liters administered via enema |
Evaluating the Broader Economic and Healthcare Impact
From an operational standpoint, deploying low-cost beverages in clinical settings underscores the resourcefulness of emergency room personnel facing refractory bowel obstructions.
Nevertheless, healthcare economists emphasize that these interventions lack standardization. Because formal randomized controlled trials and large-scale clinical trials do not exist for carbonated enemas, hospital adoption remains idiosyncratic. Medical institutions cannot build scalable healthcare models around off-label beverage protocols.
